Zymogenetics, Inc.

Bristol-myers Squibb Compnay

Blaze Bioscience, Inc.

Other

University of Washington

Scott R Presnell

Julia E Novak

Cindy A Sprecher

Donald C Foster

Angela K Hammond

Wenfeng Xu

Wayne R Kindsvogel

Richard D Holly

Andrew J Nelson

Jane A Gross

Stacey R Dillon

Zhi Chen

Janet V Johnston

Stephen R Jaspers

Teresa Gilbert

Paul O Sheppard

Brian A Fox

Francis J Grant

Monica J Huber

Zeren Gao

Mark W Rixon

Steven D Levin

Betty A Haldeman

Theodore E Whitmore

Katherine E Lewis

James William West

Darrell C Conklin

Joseph Leon Kuijper

Mark F Maurer

Brenda L Stevens

James D Kelly

Steven D Hughes

Cameron Brandt

Mohan Srinivasan

Josephine M Cardarelli

Guodong Chen

Stanley Richard Krystek, Jr

Andrew Lawrence Feldhaus

Alison Witte

Yue Yao

Indrani Chakraborty

Debra G Gilbertson

Pallavur V Sivakumar

Janine M Bilsborough

Charles E Hart

Kevin M Klucher

Si Lok

David W Taft

Emma E Moore

Robert Mabry

Steven K Burkhead

Sarah L Pownder

Natalie Winblade Nairn

Mark R Stroud

David P Yee

Dennis M Miller

Karen L Madden

George Robert Mabry, Iii

Susan Wong

Thomas D Kempe

Hui Wei

Lumelle A Schneeweis

Wen-feng Xu

Claudia Jochheim

Theresa Martinez

Eugene C Yi

Joyce M Lehner

Ross C Hoffman

Valorie R Wiss

Kelly Byrnes-Blake

Maria M Dasovich

Rolf E Kuestner

Catherine E Lofton-Day

Randal Henne

Steven Sheriff

Stacey J Hansen

Marshall D Snavely

Robyn L Adams

Anna C Jelmberg

Emily C Costerison

Thomas Edwards

Greg T Hermanson

Kenneth Grabstein

Brent Meengs

Steven K Burkhard

Cameron S Brandt

Monica Huber

Nels B Hamacher

Susan C Wong

Stanley R Krystek

Mian Gao

Tracy Arakaki

Kateri Atkins

Noah Ditto

George R Mabry

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

Tissue-homing peptide conjugates and methods of use thereof

Peptide-immuno-oncology agent complexes ('peptide-I/O complexes') that can home, target, migrate to, are directed to, are retained by, accumulate in, penetrate, or bind to the tumor microenvironment, tumor tissues, or cells or compartments or cytosol of cells thereof, or any combination thereof, are disclosed. Additionally disclosed are peptide-I/O complexes that can cross the blood-brain barrier. Pharmaceutical compositions and uses for peptide-I/O complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an immuno-oncology agent (“I/O”) to the tumor microenvironment. Targeted compositions of the disclosure can deliver peptide-I/O complexes to target regions, tissues, structures or cells targeted by the peptide.

Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

Methods of treatment using IL-23p19 monoclonal antibodies

Cartilage-homing peptide conjugates and methods of use thereof

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.

Use of IL-17A and IL-17F cross-reactive monoclonal antibodies for treating inflammatory diseases

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Treating inflammation with IL-17/IL-23 bispecific antibodies

IL-23p19 monoclonal antibodies

Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodies

Methods of treating inflammation using IL-17A and IL-17F cross-reactive monoclonal antibodies

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.

Monoclonal antibodies that bind both IL-17A and IL-17F

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Use of an IL-17/IL-23 bispecific antibody for treating inflammation

Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodies

Disclosed are antagonists of PDGF receptor &#x3b2; (PDGFR&#x3b2;) and VEGF-A, including neutralizing anti-PDGFR&#x3b2; and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR&#x3b2; and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR&#x3b2; and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR&#x3b2; and/or VEGF-A antagonist.

Compositions and methods for inhibiting PDGFRbeta and VEGF-A

IL-17A/F cross-reactive monoclonal antibodies and methods of using the same

Growing community of inventors

Tacoma, WA, United States of America

Scott R Presnell